(Q79839629)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

acute promyelocytic leukemia

26 December 2019

main subject

1 reference

1 reference

Guillermo Garcia-Manero

9

object named as

Guillermo Garcia-Manero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

3

Elihu H Estey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Ahmed Aribi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Hagop M Kantarjian

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Charles A Koller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Deborah A Thomas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Steven M Kornblau

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Stefan H Faderl

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Nakia M Laddie

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Jorge E Cortes

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

number of pages

5

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

1355-1359

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

The unique aspects of acute promyelocytic leukemia

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

Acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

Treatment options for relapsed acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22524

7 January 2021

Identifiers

DOI

10.1002/CNCR.22524

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326049%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference